BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11086723)

  • 1. Androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase.
    Ngatcha BT; Luu-The V; Poirier D
    Bioorg Med Chem Lett; 2000 Nov; 10(22):2533-6. PubMed ID: 11086723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androsterone 3alpha-ether-3beta-substituted and androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: chemical synthesis and structure-activity relationship.
    Tchédam Ngatcha B; Luu-The V; Labrie F; Poirier D
    J Med Chem; 2005 Aug; 48(16):5257-68. PubMed ID: 16078844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3Beta-alkyl-androsterones as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: inhibitory potency in intact cells, selectivity towards isoforms 1, 2, 5 and 7, binding affinity for steroid receptors, and proliferative/antiproliferative activities on AR+ and ER+ cell lines.
    Ngatcha BT; Laplante Y; Labrie F; Luu-The V; Poirier D
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):225-32. PubMed ID: 16359782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of 3-substituted-androsterone derivatives as potent inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
    Maltais R; Fournier MA; Poirier D
    Bioorg Med Chem; 2011 Aug; 19(15):4652-68. PubMed ID: 21741247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androsterone derivatives substituted at position 16: chemical synthesis, inhibition of type 3 17beta-hydroxysteroid dehydrogenase, binding affinity for steroid receptors and proliferative/antiproliferative activity on Shionogi (AR+) cells.
    Tchédam-Ngatcha B; Luu-The V; Poirier D
    J Enzyme Inhib Med Chem; 2002 Jun; 17(3):155-65. PubMed ID: 12443041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo evaluation of a 3β-androsterone derivative as inhibitor of 17β-hydroxysteroid dehydrogenase type 3.
    Roy J; Fournier MA; Maltais R; Kenmogne LC; Poirier D
    J Steroid Biochem Mol Biol; 2014 May; 141():44-51. PubMed ID: 24434282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of 3-spiromorpholinone androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
    Djigoué GB; Kenmogne LC; Roy J; Poirier D
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6360-2. PubMed ID: 24144853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, chemical synthesis and biological evaluation of 3-spiromorpholinone/3-spirocarbamate androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
    Djigoué GB; Kenmogne LC; Roy J; Maltais R; Poirier D
    Bioorg Med Chem; 2015 Sep; 23(17):5433-51. PubMed ID: 26277760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spironolactone-related inhibitors of type II 17beta-hydroxysteroid dehydrogenase: chemical synthesis, receptor binding affinities, and proliferative/antiproliferative activities.
    Tremblay MR; Luu-The V; Leblanc G; Noël P; Breton E; Labrie F; Poirier D
    Bioorg Med Chem; 1999 Jun; 7(6):1013-23. PubMed ID: 10428369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of type II 17beta-hydroxysteroid dehydrogenase.
    Poirier D; Bydal P; Tremblay MR; Sam KM; Luu-The V
    Mol Cell Endocrinol; 2001 Jan; 171(1-2):119-28. PubMed ID: 11165020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 16-Picolyl-androsterone derivative exhibits potent 17β-HSD3 inhibitory activity, improved metabolic stability and cytotoxic effect on various cancer cells: Synthesis, homology modeling and docking studies.
    Cortés-Benítez F; Roy J; Perreault M; Maltais R; Poirier D
    J Steroid Biochem Mol Biol; 2021 Jun; 210():105846. PubMed ID: 33609690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of steroidogenesis and steroidogenic enzyme functions.
    Luu-The V
    J Steroid Biochem Mol Biol; 2013 Sep; 137():176-82. PubMed ID: 23770321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
    Bellavance E; Luu-The V; Poirier D
    J Med Chem; 2009 Dec; 52(23):7488-502. PubMed ID: 19772289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of phenyl substituted 1H-1,2,4-triazoles as non-steroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 2.
    Al-Soud YA; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    Arch Pharm (Weinheim); 2012 Aug; 345(8):610-21. PubMed ID: 22532378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A- and D-Ring Structural Modifications of an Androsterone Derivative Inhibiting 17β-Hydroxysteroid Dehydrogenase Type 3: Chemical Synthesis and Structure-Activity Relationships.
    Cortés-Benítez F; Roy J; Perreault M; Maltais R; Poirier D
    J Med Chem; 2019 Aug; 62(15):7070-7088. PubMed ID: 31268309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and breast cancer.
    Hilborn E; Stål O; Jansson A
    Oncotarget; 2017 May; 8(18):30552-30562. PubMed ID: 28430630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chalcones are potent inhibitors of aromatase and 17beta-hydroxysteroid dehydrogenase activities.
    Le Bail JC; Pouget C; Fagnere C; Basly JP; Chulia AJ; Habrioux G
    Life Sci; 2001 Jan; 68(7):751-61. PubMed ID: 11205867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel, potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities.
    Perspicace E; Cozzoli L; Gargano EM; Hanke N; Carotti A; Hartmann RW; Marchais-Oberwinkler S
    Eur J Med Chem; 2014 Aug; 83():317-37. PubMed ID: 24974351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sebocytes are the key regulators of androgen homeostasis in human skin.
    Fritsch M; Orfanos CE; Zouboulis CC
    J Invest Dermatol; 2001 May; 116(5):793-800. PubMed ID: 11348472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and in vitro evaluation of 4-androstene-3,17-dione/adenosine hybrid compounds as bisubstrate inhibitors of type 3 17beta-hydroxysteroid dehydrogenase.
    Bérubé M; Laplante Y; Poirier D
    Med Chem; 2006 Jul; 2(4):329-47. PubMed ID: 16848745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.